Soligenix taps ATM market, authorizes $2.96 M equity sale amid volatile share price

Soligenix’s latest filing – a Form 424B5 dated May 28, 2026 – authorizes the sale of up to $2,956,000 of its common shares. Unlike a traditional IPO, the supplement does not lock in a fixed price; instead, the company will sell shares at prevailing market rates under its existing ATM agreement.

The filing lists a public float of $24.5 million, representing 17,261,708 non‑affiliate shares priced at $1.42 each. That float sits well below the $75 million threshold that would lift the one‑third public‑float limitation, meaning Soligenix can only sell a maximum of one‑third of its float in any 12‑month period. With $5.2 million of securities already sold in the prior year, the new $2.96 million authorization pushes the company toward that ceiling.

Pricing dynamics are stark. The last reported sale price on April 27 was $1.42 per share, but by May 27 the market had driven the price down to $0.87. Because the ATM will execute at whatever price the market offers, the ultimate proceeds could vary widely. The filing does not disclose an underwriting discount, net‑proceeds estimate, or an overallotment option – typical placeholders in a more detailed prospectus – underscoring the simplicity of an ATM structure.

Use of proceeds remains vague. The supplement provides no earmarked allocation for the cash, merely authorizing the sale. In the absence of a disclosed plan, investors must infer that the funds will likely support general corporate purposes, working capital, or debt repayment – the usual language in ATM filings – but the filing itself offers no specifics.

Underwriting syndicate is also absent from the document. The prospectus supplement does not name a lead manager or a syndicate, suggesting Soligenix will rely on the broker‑dealer already party to its ATM agreement rather than a traditional underwriting team.

Risk factors are incorporated by reference to the company’s prior prospectus and its most recent Form 10‑K. While the supplement does not enumerate new risks, the standard concerns for an ATM remain: dilution of existing shareholders, the possibility of a lock‑up period restricting insider sales, and the inherent uncertainty of market‑driven pricing.

Market context adds another layer. Soligenix’s stock has shown notable volatility, halving in price over a single month. The broader secondary‑market environment in 2026 has been mixed, with investors showing caution toward smaller‑cap biotech issuances. Analysts who cover the ticker have been sparse, and the modest size of this ATM – less than $3 million – signals a measured capital raise rather than a bold expansion.

In short, Soligenix is opting for a low‑key, market‑price‑driven equity infusion. The $2.96 million ceiling is modest, the pricing window is uncertain, and the filing offers few details beyond the basic mechanics. Whether the cash will shore up the balance sheet or fund upcoming research milestones remains to be seen, but the move underscores the company’s reliance on flexible, incremental financing in a choppy market.